U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H23ClFNO2
Molecular Weight 375.8649
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HALOPERIDOL

SMILES

C(CC(=O)c1ccc(cc1)F)CN2CCC(CC2)(c3ccc(cc3)Cl)O

InChI

InChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

HIDE SMILES / InChI

Molecular Formula C21H23ClFNO2
Molecular Weight 375.8649
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf

Haloperidol is a phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. Haloperidol also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ. Haloperidol is marketed under the trade name Haldol among others.

Originator

Curator's Comment:: Haloperidol was synthesized on the 11th of February 1958 at the Janssen Laboratories, in Belgium.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
17.0 nM [EC50]
53.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HALDOL

Approved Use

HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder.

Launch Date

5.059584E11
Primary
HALDOL

Approved Use

HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder.

Launch Date

5.059584E11
Doses

Doses

DosePopulationAdverse events​
0.9 mg single, oral
Overdose
Dose: 0.9 mg
Route: oral
Route: single
Dose: 0.9 mg
Sources:
unknown, 11 years
n = 1
Health Status: unknown
Age Group: 11 years
Sex: M
Population Size: 1
Sources:
Other AEs: Drowsiness...
Other AEs:
Drowsiness (1 patient)
Sources:
2 mg 4 times / day multiple, intramuscular
Recommended
Dose: 2 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 2 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: dementia-related psychosis
Age Group: adult
Sources:
5 mg 3 times / day multiple, oral
Recommended
Dose: 5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 5 mg, 3 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: dementia-related psychosis
Age Group: adult
Sources:
10 mg 2 times / day steady, intravenous
Dose: 10 mg, 2 times / day
Route: intravenous
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 192
Health Status: unhealthy
Condition: Delirium
Population Size: 192
Sources:
Other AEs: Torsades de pointes, Electrocardiogram QTc interval prolonged...
Other AEs:
Torsades de pointes (serious, 2 patients)
Electrocardiogram QTc interval prolonged (below serious, 13 patients)
Sources:
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Other AEs: Cheilitis, Constipation...
Other AEs:
Cheilitis (below serious, 1 patient)
Constipation (below serious, 2 patients)
Salivary hypersecretion (below serious, 1 patient)
Vomiting (below serious, 1 patient)
Malaise (below serious, 2 patients)
Thirst (below serious, 1 patient)
Fall (below serious, 1 patient)
Blood pressure decreased (below serious, 1 patient)
Weight increased (below serious, 1 patient)
Increased appetite (below serious, 1 patient)
Arthralgia (below serious, 1 patient)
Osteoarthritis (below serious, 1 patient)
Akathisia (below serious, 3 patients)
Dystonia (below serious, 3 patients)
Headache (below serious, 1 patient)
Sedation (below serious, 1 patient)
Tremor (below serious, 2 patients)
Depressive symptom (below serious, 1 patient)
Insomnia (below serious, 1 patient)
Mania (below serious, 1 patient)
Pruritus (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Drowsiness 1 patient
0.9 mg single, oral
Overdose
Dose: 0.9 mg
Route: oral
Route: single
Dose: 0.9 mg
Sources:
unknown, 11 years
n = 1
Health Status: unknown
Age Group: 11 years
Sex: M
Population Size: 1
Sources:
Electrocardiogram QTc interval prolonged below serious, 13 patients
10 mg 2 times / day steady, intravenous
Dose: 10 mg, 2 times / day
Route: intravenous
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 192
Health Status: unhealthy
Condition: Delirium
Population Size: 192
Sources:
Torsades de pointes serious, 2 patients
10 mg 2 times / day steady, intravenous
Dose: 10 mg, 2 times / day
Route: intravenous
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 192
Health Status: unhealthy
Condition: Delirium
Population Size: 192
Sources:
Arthralgia below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Blood pressure decreased below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Cheilitis below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Depressive symptom below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Fall below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Headache below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Increased appetite below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Insomnia below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Mania below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Osteoarthritis below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Pruritus below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Salivary hypersecretion below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Sedation below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Thirst below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Vomiting below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Weight increased below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Constipation below serious, 2 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Malaise below serious, 2 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Tremor below serious, 2 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Akathisia below serious, 3 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Dystonia below serious, 3 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate [Ki 7.2 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >30 uM]
no [IC50 >50 uM]
no
yes [Activation 31.6228 uM]
yes [IC50 10.7 uM]
yes [IC50 141.9 uM]
yes [IC50 2.87 uM]
yes [IC50 25.3 uM]
yes [IC50 25.4 uM]
yes [IC50 3.6 uM]
yes [IC50 4.69 uM]
yes [IC50 8.2 uM]
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely [Km 33 uM]
major
major
major
major
minor
minor
minor
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
Atypical tardive dyskinesia.
1975 May
Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.
1976 Aug
Papaverine, drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat.
1976 Jul
Parkinsonism by haloperidol and piribedil.
1978 Oct 31
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
1999
Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats.
1999
Neurotransmitter-mediated open-field behavioral action of CGRP.
1999
A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep.
1999 Apr
Sexual disturbances during clozapine and haloperidol treatment for schizophrenia.
1999 Apr
Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
1999 Aug 20
Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice.
1999 Aug 30
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
1999 Jul
Safety of amisulpride (Solian): a review of 11 clinical studies.
1999 Jul
Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.
1999 Jun
The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice.
1999 Mar
The effects of benzamide analogues on cocaine self-administration in rhesus monkeys.
1999 Nov
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
1999 Nov
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
1999 Nov 26
[The neurochemical mechanisms of the formation and consolidation of haloperidol-induced catalepsy].
1999 Nov-Dec
Inhibition of haloperidol-induced catalepsy in rats by root extracts from Piper methysticum F.
1999 Oct
Identification of quantitative trait loci for haloperidol-induced catalepsy on mouse chromosome 14.
1999 Sep
Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.
2000 Apr
The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission.
2000 Jul
Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs.
2000 Jul
Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.
2000 Mar
Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.
2000 Mar 10
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
2000 May
Haloperidol-induced catalepsy is influenced by calcium channel antagonists.
2000 May-Jun
Enhancement of haloperidol-induced catalepsy by nicotine: an investigation of possible mechanisms.
2000 Nov
Role of prolactin in chloro-S-triazine rat mammary tumorigenesis.
2000 Nov
The serotonin 5-HT(2A) receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats.
2000 Oct
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
2000 Sep
FosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration.
2001 Feb
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.
2001 Feb 13
Double activity imaging reveals distinct cellular targets of haloperidol, clozapine and dopamine D(3) receptor selective RGH-1756.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: can also be taken orally https://www.drugs.com/ppa/haloperidol.html
Parenteral medication, administered intramuscularly in doses of 2 to 5 mg, is utilized for prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms. Depending on the response of the patient, subsequent doses may be given, administered as often as every hour, although 4 to 8 hour intervals may be satisfactory.
Route of Administration: Intramuscular
10 uM Haloperidol induced a 54% decrease in the mRNA expression of ABCA1 in murineperitoneal macrophages.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:25 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:25 UTC 2021
Record UNII
J6292F8L3D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HALOPERIDOL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
HALOPERIDOL DECANOATE SPECIFIED IMPURITY G [EP]
Common Name English
HALOPERIDOL COMPONENT OF VESALIUM
Brand Name English
EUKYSTOL
Common Name English
VESALIUM COMPONENT HALOPERIDOL
Brand Name English
HALOPERIDOL [HSDB]
Common Name English
HALOPERIDOL [WHO-IP]
Common Name English
SIGAPERIDOL
Common Name English
HALDOL
Brand Name English
KESELAN
Common Name English
ALOPERIDIN
Common Name English
HALOPERIDOL [WHO-DD]
Common Name English
NSC-170973
Code English
HALOPERIDOL [EP MONOGRAPH]
Common Name English
R-1625
Code English
NSC-615296
Code English
HALOPERIDOLUM [WHO-IP LATIN]
Common Name English
SERENELFI
Common Name English
SERENASE
Common Name English
BIOPERIDOLO
Common Name English
1-BUTANONE, 4-(4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-
Systematic Name English
HALOPERIDOL [USP]
Common Name English
HALOPERIDOL [MI]
Common Name English
SERENACE
Common Name English
HALOPERIDOL [USP MONOGRAPH]
Common Name English
HALOPERIDOL DECANOATE IMPURITY, HALOPERIDOL- [USP]
Common Name English
HALOPERIDOL [MART.]
Common Name English
NEURODOL
Common Name English
LINTON
Common Name English
HALOPERIDOL [ORANGE BOOK]
Common Name English
HALOPERIDOL [USAN]
Common Name English
HALOPERIDOL [INN]
Common Name English
HALOPERIDOL [VANDF]
Common Name English
DOZIC
Common Name English
HALOPERIDOL [USP-RS]
Common Name English
Classification Tree Code System Code
LIVERTOX 476
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
NDF-RT N0000180182
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
WHO-ATC N05AD01
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 24.1
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
WHO-VATC QN05AD01
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
NCI_THESAURUS C323
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
NCI_THESAURUS C66883
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
HALOPERIDOL
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY Description: A white to faintly yellowish, amorphous or microcrystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 50 parts of ethanol (~750 g/l) TS and in 200 parts of ether R. Category: Neuroleptic. Storage: Haloperidol should be kept in a well-closed container, protected from light. Definition: Haloperidol contains not less than 98.0% and not more than 101.0% of C21H23ClFNO2, calculated with reference to the dried substance.
IUPHAR
86
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
DRUG BANK
DB00502
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
HSDB
3093
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
LACTMED
Haloperidol
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
WIKIPEDIA
HALOPERIDOL
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
FDA UNII
J6292F8L3D
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
RXCUI
5093
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY RxNorm
CAS
52-86-8
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
PUBCHEM
3559
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL54
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
MESH
D006220
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
USP_CATALOG
1303002
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
200-155-6
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
MERCK INDEX
M5904
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C537
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
EPA CompTox
52-86-8
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
EVMPD
SUB08005MIG
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
INN
918
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
DRUG CENTRAL
1353
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
METABOLITE TOXIC -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY